Printable: How important is the FDA approval of once-weekly dosage of Kyprolis (carfilzomib) for multiple myeloma patients?

How important is the FDA approval of once-weekly dosage of Kyprolis (carfilzomib) for multiple myeloma patients? (https://www.myeloma.org/videos/how-important-fda-approval-once-weekly-dosage-kyprolis-carfilzomib-multiple-myeloma-patients)

In this week’s video, Dr. Brian G.M. Durie explains the results of the A.R.R.O.W. trial, which proved the efficacy and safety of once-a-week dosing of Kyprolis for myeloma patients.

BOTTOM LINE:
The FDA approval of once-weekly dosing of Kyprolis is effective, more convenient for patients, and doesn’t lead to additional toxicities.

Author

Dr. Brian GM Durie (https://www.myeloma.org/Brian-Durie-md)

Video

Series

Ask Dr. Durie (https://www.myeloma.org/taxonomy/term/19)

Old Id

1538

Ask a Question

Please note that Ask Dr. Durie has been discontinued, and it was designed to address myeloma questions of the broadest possible audience interest. If you have a question of a personal nature, please contact our InfoLine Coordinators at 800.452.2873 or [email protected] (mailto:[email protected]) (Please do not send email attachments or lab reports.).

Image of Dr. Brian G.M. Durie Dr. Brian G.M. Durie (1942-2025) was the co-founder of the IMF. He was a Professor of Medicine, Hematologist/Oncologist, and Honoree MD at the University of Brussels.